News | October 16, 2024
Tim Buckley elected to Pfizer’s Board of Directors
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Pfizer's decision is based on the totality of clinical data
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
